Cargando…

Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit

BACKGROUND: Children with Idiopathic Short Stature do not attain a normal adult height. The improvement of adult height with treatment with recombinant human growth hormone (rhGH), at doses of 0.16 to 0.28 mg/kg/week is modest, usually less that 4 cm, and they remain short as adults. The benefit obt...

Descripción completa

Detalles Bibliográficos
Autores principales: Sotos, Juan F, Tokar, Naomi J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114101/
https://www.ncbi.nlm.nih.gov/pubmed/25075207
http://dx.doi.org/10.1186/1687-9856-2014-15
_version_ 1782328390955565056
author Sotos, Juan F
Tokar, Naomi J
author_facet Sotos, Juan F
Tokar, Naomi J
author_sort Sotos, Juan F
collection PubMed
description BACKGROUND: Children with Idiopathic Short Stature do not attain a normal adult height. The improvement of adult height with treatment with recombinant human growth hormone (rhGH), at doses of 0.16 to 0.28 mg/kg/week is modest, usually less that 4 cm, and they remain short as adults. The benefit obtained seems dose dependent and benefits of 7.0 to 8.0 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week, but the number of studies is limited. The topic has remained controversial. OBJECTIVE: The objective was to conduct a retrospective analysis of our experience with 123 children with ISS treated with 0.32 ± 0.03 mg/kg/week of rhGH, with the aim of comparing the different subgroups of non-familial short stature, familial short stature, normal puberty, and delayed puberty and to assess the benefit by comparison with 305 untreated historical controls, from nine different randomized and nonrandomized controlled studies. RESULTS: Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of -0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females. In the analysis of the subgroups, the adult height and adult height gain of children with non-familial short stature were significantly higher than of familial short stature. No difference was found in the cohorts with normal or delayed puberty in any of the subgroups, except between the non-familial short stature and familial short stature puberty cohorts. This has implications for the interpretation of the benefit of treatment in studies where the number of children with familial short stature in the controls or treated subjects is not known. The treatment was safe. There were no significant adverse events. The IGF-1 values were essentially within the levels expected for the stages of puberty. CONCLUSION: Our experience was quite positive with normalization of the heights and growth of the children during childhood and the attainment of normal adult heights, the main two aims of treatment.
format Online
Article
Text
id pubmed-4114101
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41141012014-07-30 Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit Sotos, Juan F Tokar, Naomi J Int J Pediatr Endocrinol Research BACKGROUND: Children with Idiopathic Short Stature do not attain a normal adult height. The improvement of adult height with treatment with recombinant human growth hormone (rhGH), at doses of 0.16 to 0.28 mg/kg/week is modest, usually less that 4 cm, and they remain short as adults. The benefit obtained seems dose dependent and benefits of 7.0 to 8.0 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week, but the number of studies is limited. The topic has remained controversial. OBJECTIVE: The objective was to conduct a retrospective analysis of our experience with 123 children with ISS treated with 0.32 ± 0.03 mg/kg/week of rhGH, with the aim of comparing the different subgroups of non-familial short stature, familial short stature, normal puberty, and delayed puberty and to assess the benefit by comparison with 305 untreated historical controls, from nine different randomized and nonrandomized controlled studies. RESULTS: Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of -0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females. In the analysis of the subgroups, the adult height and adult height gain of children with non-familial short stature were significantly higher than of familial short stature. No difference was found in the cohorts with normal or delayed puberty in any of the subgroups, except between the non-familial short stature and familial short stature puberty cohorts. This has implications for the interpretation of the benefit of treatment in studies where the number of children with familial short stature in the controls or treated subjects is not known. The treatment was safe. There were no significant adverse events. The IGF-1 values were essentially within the levels expected for the stages of puberty. CONCLUSION: Our experience was quite positive with normalization of the heights and growth of the children during childhood and the attainment of normal adult heights, the main two aims of treatment. BioMed Central 2014 2014-07-16 /pmc/articles/PMC4114101/ /pubmed/25075207 http://dx.doi.org/10.1186/1687-9856-2014-15 Text en Copyright © 2014 Sotos and Tokar; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sotos, Juan F
Tokar, Naomi J
Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
title Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
title_full Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
title_fullStr Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
title_full_unstemmed Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
title_short Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
title_sort growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114101/
https://www.ncbi.nlm.nih.gov/pubmed/25075207
http://dx.doi.org/10.1186/1687-9856-2014-15
work_keys_str_mv AT sotosjuanf growthhormonesignificantlyincreasestheadultheightofchildrenwithidiopathicshortstaturecomparisonofsubgroupsandbenefit
AT tokarnaomij growthhormonesignificantlyincreasestheadultheightofchildrenwithidiopathicshortstaturecomparisonofsubgroupsandbenefit